Medicine Canada
A community for Canadian physicians and medical professionals
🍁 While this community is intended for Canadian discussions, you are free to post about other medical systems. We're all in this together :)
Related Communities
- Medical Community Hub
- Medicine
- Medicine Canada (📍)
- Premed
- Premed Canada
- Public Health
For better links and descriptions, see the pinned post in the Medical Community Hub (!medicine@lemmy.world)
Rules
-
No requests for professional advice or general medical information. Please do not solicit medical advice or share personal health anecdotes about yourself or others.
-
No promotions, advertisements, surveys, or petitions.
-
Link to high-quality, original research whenever possible: Posts which rely on or reference scientific data (e.g. an announcement about a medical breakthrough) should link to the original research in peer-reviewed medical journals or respectable news sources as judged by the moderators. Sensationalized titles, misrepresentation of results, or promotion of blatantly bad science may lead to removal.
-
Act professionally and decently: /r/medicine is a public forum that represents the medical community and comments should reflect this. Please keep disagreement civil and focused on issues.
-
Protect patient confidentiality. Please anonymize cases and remove any patient-identifiable information.
-
No memes or low-effort posts: Memes, image links (including social media screenshots), images of text, or other low-effort posts or comments are not allowed.
These rules have been modelled after /r/medicine. While some rules were modified or skipped as this is a much smaller community, we can revisit the rules as we go. Thank you :)
view the rest of the comments
This is the best summary I could come up with:
A British Columbia provincial policy that forced people with chronic illnesses such as Crohn’s disease and rheumatoid arthritis to switch to cheaper medications saved the province more than $730-million over five years, according to a new government report.
government said Friday that the money freed up through its biosimilar switching plan allowed the province to expand public coverage of other drugs and devices, including Trikafta, a life-changing treatment for cystic fibrosis and continuous glucose monitors for people with diabetes.
“When this policy was introduced, it was highly controversial,” said Michael Law, a University of British Columbia professor who holds a Canada Research Chair in Access to Medicines.
Biosimilars are near-copies of the original, brand-name versions of biologics, a class of drugs manufactured from living cells.
As the first biologics came off patent, Health Canada began approving biosimilars that were almost like generics but were treated differently in practice and policy.
Biosimilars aren’t interchangeable at the pharmacy, which means doctors must write new prescriptions for the less-expensive product.
The original article contains 479 words, the summary contains 167 words. Saved 65%. I'm a bot and I'm open source!